Medicines

Brexit could delay cancer drugs by up to two years


British patients could wait longer to access new cancer drugs if it leaves the European Union as planned, a former head of the drug regulatory agency has warned.

In an interview with the BBC’s Today Programme the former chair of the Medicines and Healthcare Products Regulatory Agency, Alasdair Breckenridge, said drug companies may need to pay for a separate assessment of their product for use in the UK once it leaves the European market.

This could mean companies will prioritise winning approval for access to the larger European market ahead of the UK market, he said.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic